Moderate to Severe Atopic Dermatitis Clinical Trial
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06012812 -
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT05549947 -
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT06136741 -
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT06099704 -
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
|
||
Completed |
NCT03568162 -
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT00148746 -
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
|
N/A | |
Recruiting |
NCT05702268 -
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Not yet recruiting |
NCT06468956 -
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05997927 -
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Not yet recruiting |
NCT05197023 -
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
|
Phase 1 | |
Recruiting |
NCT06239311 -
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
|
Phase 3 | |
Terminated |
NCT01286220 -
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
|
N/A |